The yin and yang of increased β-adrenergic signaling: β1-adrenergic genetic polymorphism and protection against acute myocardial ischemic injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 4, 2006, Pages

  Pleger, Sven T ^a   Koch, Walter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; GENETIC POLYMORPHISM; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CONVALESCENCE; GENETIC PREDISPOSITION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HUMAN; NOTE; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RECEPTORS, ADRENERGIC, BETA-1; RECOVERY OF FUNCTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646080357     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01156.2005     Document Type: Editorial

References (16)

1. 1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol 290: H1427-H1432, 2006.
2. American Heart Association. Heart Disease and Stroke Statistics [Online]. Am. Heart Assoc., Natl. Cent., Dallas, Tex. http://www.american-heart.org [January 2006].
3. Best Trial Investigators. A trial of the β-adrenergic blocker bucindolol in patients with advanced heart failure. N Engl J Med 344: 1659-1667, 2001.
4. Bristow M, Krause-Steinrauf H, Abraham W, Liang CS, Hattler B, Kruger S, and Zelis R. Sympatholytic effect of bucindolol adversely affected survival, and was disproportionally observed in the class IV subgroup of BEST (Abstract). Circulation 104: II-755, 2001.
5. 2-adrenergic receptor and expression of a β-adrenergic receptor kinase-1 (βARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res 85: 1077-1084, 1999.
6. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, and Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 256: 34-41, 2000.
7. Lefkowitz RJ and Shenoy SK. Transduction of receptor signals by β-arrestins. Science 308: 512-517, 2005.
8. Leineweber K, Buscher R, Bruck H, and Brodde OE. Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369: 1-22, 2004.
9. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277: 30429-30435, 2002.
10. 1- adrenergic receptor. J Biol Chem 274: 12670-12674, 1999.
11. 1-adrenoceptor: identification and rapid screening assay. Lancet 353: 897, 1999.
12. Rockman HA, Koch WJ, and Lefkowtiz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 415: 206-212, 2002.
13. Small KM, McGraw DW, and Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43: 381-411, 2003.
14. 2C adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135-1142, 2002.
15. 1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 144: 840-846, 2002.
16. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98: 1607-1612, 2001.